Ng, Kimmie
Hendifar, Andrew
Starodub, Alexander
Chaves, Jorge
Yang, Yingsi
Koh, Brian
Barbie, David
Hahn, William C.
Fuchs, Charles S.
Funding for this research was provided by:
National Institutes of Health (P50 CA127003, R01 CA118553, R01 CA169141)
Gilead Sciences
Article History
Received: 6 July 2018
Accepted: 20 July 2018
First Online: 30 July 2018
Compliance with ethical standards
:
: KN: research funding from Gilead, Genentech, Tarrex, and Pharmavite, and advisory board for Bayer. AH: consultant/advisory role for Genentech, Ipsen, Novartis, Perthera. JC: None. AS: consulting/advisory role for Sandoz, Bayer, and speakers bureau for BMS. YY: employee of Gilead Sciences, Inc. BK: employee of Gilead Sciences, Inc. DB: consultant for N of One. WCH: None. CSF: consultant for Eli Lilly, Entrinsic Health, Genentech, Merck, Sanofi, Five Prime Therapeutics, Merrimack, Bayer, Agios, Taiho, Kew, Bain Capital, Unum, and board member for CytomX.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.